Browse by author
Lookup NU author(s): Professor Alan Boddy, Mike Cole, Professor Andrew Pearson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
1. Cyclophosphamide pharmacokinetics were measured in 38 children with cancer. 2. A high degree of inter-patient variation was seen in all pharmacokinetic parameters. Cyclophosphamide half-life varied between 1.1. and 16.8 h, clearance varied between 1.2 and 10.6 l h-1 m-2 and volume of distribution varied between 0.26 and 1.48 l kg-1. 3. The half-life of cyclophosphamide was prolonged at high dose levels (P = 0.008). 4. Children who had received prior treatment with dexamethasone showed a mean increase in clearance of 2.5 1 h-1 m-2 (P = 0.001) presumably as a result of CYP450 enzyme induction. 5. Treatment with alopurinol or chlorpromazine was associated with a significant increase in cyclophosphamide half-life (P < 0.001 in both cases). 6. Dose and concurrent treatment may influence cyclophosphamide metabolism in vivo and thus potentially alter the drugs therapeutic effect.
Author(s): Yule, S., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M., Pearson, A. D. J., Idle, J.
Publication type: Article
Publication status: Published
Journal: British Journal of Clinical Pharmacology
Year: 1996
Volume: 41
Issue: 1
Pages: 13-19
Print publication date: 01/01/1996
ISSN (print): 0306-5251
ISSN (electronic): 1365-2125
URL: http://dx.doi.org/10.1111/j.1365-2125.1996.tb00153.x
DOI: 10.1111/j.1365-2125.1996.tb00153.x
PubMed id: 8824688
Altmetrics provided by Altmetric
